Q&A: Foundation Private Equity’s Jason Sambanju
Having made his name in Asia secondaries at Paul Capital, Jason Sambanju struck out on his own in 2017 with Foundation Private Equity. He explains why there is room for a local GP dedicated to LP-style deals
Q: What can you bring to secondaries in Asia that the market doesn’t already have? A: We are a regional, homegrown secondaries firm that only does LP-style secondaries. All our brethren straddle two...
Co-Stone leads $43m round for China biosynthesis player
Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners closes debut fund on $137m
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
US regulator gets access to Chinese audits
The threat of delisting that has haunted Chinese companies that trade on US exchanges appears to have receded after the US regulators announced they had gained full access to the audits of these companies for the first time.